Trial of Patidegib Gel 2%, 4%, & Vehicle to Decrease the Number of

Status Completed

Clinical Trial Summary

Multicenter, double-blind, randomized, vehicle-controlled study that evaluates the efficacy and safety of patidegib gel 2% and 4% in comparison with vehicle in participants at least 18 years of age that meet the diagnostic criteria for basal cell nevus syndrome (BCNS). Participants will be randomized to receive patidegib gel 2%, patidegib gel 4%, or the vehicle gel for a 26-week treatment period.

Clinical Trial Description

Participants who meet the study entry criteria will be randomized in a 1:1:1 ratio to receive patidegib gel 2%, patidegib gel 4%, vehicle gel. One or two tubes of the assigned study drug will be dispensed to the participant at the Baseline visit. Additional tubes will be dispensed at subsequent visits through Week 22. The study drug will be applied topically to the entire face as well as to treatment-targeted surgically eligible basal cell carcinomas (SEBs) at other anatomical sites twice daily for 26 weeks of treatment.

Information on reported and observed adverse events will be obtained at each visit. An abbreviated physical examination will be performed at Baseline, Week 14, and Week 26.

At Baseline and Weeks 6, 10, 14, 18, 22, and 26, all visible basal cell carcinomas (BCCs) (excluding areas below the knees) will be identified by the Investigator, circled in ink, photographed, measured, and recorded on a body diagram. Treatment-targeted SEBs (defined as the 5 SEBs on the face and/or other anatomical areas identified at Baseline as SEBs) will be treated during the 26-week treatment phase. If a participant has 5 eligible previously untreated facial SEBs (excluding tumors on nose and eyelids) these tumors will be the participant's 5 baseline treatment-targeted SEBs and non-facial baseline SEBs will not be treated with study drug. Tumors to be measured and mapped include the 5 baseline treatment-targeted tumors as well as all other facial tumors including those on the eyelids and the nose. In addition, up to 10 non-treatment-targeted non-facial tumors will also be measured and mapped. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02762084
Study type	Interventional
Source	PellePharm, Inc.
Contact
Status	Completed
Phase	Phase 2
Start date	June 6, 2016
Completion date	April 24, 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02550678` - A Study of the Efficacy and Safety of ASN-002 in Adult Patients With Low-risk Nodular Basal Cell Carcinoma	Phase 1/Phase 2
Completed	`NCT00555633` - Use of an SPF30 Sunscreen and an After-sun-lotion in Skin Cancer Risk Patients	N/A
Recruiting	`NCT03483441` - Vitamin D and Photodynamic Therapy for Treatment of BCC in BCNS	Phase 1
Active, not recruiting	`NCT03467789` - Vitamin D as a Nutritional Neoadjuvant During Photodynamic Therapy of Basal Cell Carcinoma	Phase 1
Recruiting	`NCT05463757` - Oral Hedgehog Inhibitors in the Treatment of Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study
Terminated	`NCT04308395` - Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)	Phase 3
Withdrawn	`NCT03767439` - Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome	Phase 2
Completed	`NCT04416516` - Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor	Phase 2
Recruiting	`NCT06330350` - Qualitative Study in Patients With Genodermatoses and Healthcare Professionals on Reproductive Counselling
Enrolling by invitation	`NCT06330324` - Reproductive Options in Inherited Skin Diseases
Terminated	`NCT02303041` - Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma	Phase 2
Completed	`NCT02100371` - Study of BMS-833923 in Two Specific Patients With Basal Cell Nevus Syndrome	N/A
Completed	`NCT03703310` - Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)	Phase 3
Completed	`NCT02157623` - Blue vs Red Light During Levulan Based Photodynamic Therapy in Patients With Basal Cell Nevus Syndrome	N/A
Completed	`NCT00957229` - To Determine The Efficacy and Safety of GDC-0449 in Patients With Basal Cell Nevus Syndrome (BCNS)	Phase 2
Completed	`NCT01556009` - Trial Comparing the Effects of Intermittent Vismodegib vs. PDT in Patients With Multiple Basal Cell Carcinomas	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms